PMC:7309518 / 2078-2851 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T36","span":{"begin":177,"end":185},"obj":"Disease"},{"id":"T37","span":{"begin":207,"end":210},"obj":"Disease"},{"id":"T38","span":{"begin":232,"end":253},"obj":"Disease"},{"id":"T39","span":{"begin":331,"end":339},"obj":"Disease"},{"id":"T40","span":{"begin":340,"end":349},"obj":"Disease"},{"id":"T41","span":{"begin":491,"end":512},"obj":"Disease"},{"id":"T42","span":{"begin":576,"end":585},"obj":"Disease"},{"id":"T43","span":{"begin":588,"end":612},"obj":"Disease"},{"id":"T44","span":{"begin":614,"end":618},"obj":"Disease"}],"attributes":[{"id":"A36","pred":"mondo_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A37","pred":"mondo_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A38","pred":"mondo_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/MONDO_0005071"},{"id":"A39","pred":"mondo_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A40","pred":"mondo_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A41","pred":"mondo_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/MONDO_0005071"},{"id":"A42","pred":"mondo_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A43","pred":"mondo_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A44","pred":"mondo_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"}],"text":"dressed; the role of complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed.\n\nConclusions\nEmerging data indicate that COVID-19 can trigger not only GBS but other autoimmune neurological diseases necessitating vigilance for early diagnosis and therapy initiation. Although COVID-19 infection, like most other viruses, can potentially worsen patients with pre-existing autoimmunity, there is no evidence that patients with autoimmune neurological diseases stable on common immunotherapies are facing increased risks of infection.\n\nGuillain-Barré syndromes (GBSs) comprise a spectrum of polyneuropathies characterized by acute (within 1–4 weeks) ascending motor weakness, mild or moderate sensory abnormalities, occas"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T10","span":{"begin":367,"end":374},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T11","span":{"begin":546,"end":556},"obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"id":"T12","span":{"begin":629,"end":630},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"dressed; the role of complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed.\n\nConclusions\nEmerging data indicate that COVID-19 can trigger not only GBS but other autoimmune neurological diseases necessitating vigilance for early diagnosis and therapy initiation. Although COVID-19 infection, like most other viruses, can potentially worsen patients with pre-existing autoimmunity, there is no evidence that patients with autoimmune neurological diseases stable on common immunotherapies are facing increased risks of infection.\n\nGuillain-Barré syndromes (GBSs) comprise a spectrum of polyneuropathies characterized by acute (within 1–4 weeks) ascending motor weakness, mild or moderate sensory abnormalities, occas"}

{"project":"LitCovid-PubTator","denotations":[{"id":"86","span":{"begin":399,"end":407},"obj":"Species"},{"id":"87","span":{"begin":466,"end":474},"obj":"Species"},{"id":"88","span":{"begin":177,"end":185},"obj":"Disease"},{"id":"89","span":{"begin":221,"end":253},"obj":"Disease"},{"id":"90","span":{"begin":331,"end":339},"obj":"Disease"},{"id":"91","span":{"begin":340,"end":349},"obj":"Disease"},{"id":"92","span":{"begin":480,"end":512},"obj":"Disease"},{"id":"93","span":{"begin":576,"end":585},"obj":"Disease"},{"id":"132","span":{"begin":614,"end":618},"obj":"Disease"},{"id":"133","span":{"begin":643,"end":659},"obj":"Disease"},{"id":"134","span":{"begin":718,"end":726},"obj":"Disease"},{"id":"135","span":{"begin":745,"end":766},"obj":"Disease"}],"attributes":[{"id":"A86","pred":"tao:has_database_id","subj":"86","obj":"Tax:9606"},{"id":"A87","pred":"tao:has_database_id","subj":"87","obj":"Tax:9606"},{"id":"A88","pred":"tao:has_database_id","subj":"88","obj":"MESH:C000657245"},{"id":"A89","pred":"tao:has_database_id","subj":"89","obj":"MESH:D020274"},{"id":"A90","pred":"tao:has_database_id","subj":"90","obj":"MESH:C000657245"},{"id":"A91","pred":"tao:has_database_id","subj":"91","obj":"MESH:D007239"},{"id":"A92","pred":"tao:has_database_id","subj":"92","obj":"MESH:D020274"},{"id":"A93","pred":"tao:has_database_id","subj":"93","obj":"MESH:D007239"},{"id":"A133","pred":"tao:has_database_id","subj":"133","obj":"MESH:D011115"},{"id":"A134","pred":"tao:has_database_id","subj":"134","obj":"MESH:D018908"},{"id":"A135","pred":"tao:has_database_id","subj":"135","obj":"MESH:D012678"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"dressed; the role of complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed.\n\nConclusions\nEmerging data indicate that COVID-19 can trigger not only GBS but other autoimmune neurological diseases necessitating vigilance for early diagnosis and therapy initiation. Although COVID-19 infection, like most other viruses, can potentially worsen patients with pre-existing autoimmunity, there is no evidence that patients with autoimmune neurological diseases stable on common immunotherapies are facing increased risks of infection.\n\nGuillain-Barré syndromes (GBSs) comprise a spectrum of polyneuropathies characterized by acute (within 1–4 weeks) ascending motor weakness, mild or moderate sensory abnormalities, occas"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":35,"end":50},"obj":"http://purl.obolibrary.org/obo/GO_0045087"}],"text":"dressed; the role of complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed.\n\nConclusions\nEmerging data indicate that COVID-19 can trigger not only GBS but other autoimmune neurological diseases necessitating vigilance for early diagnosis and therapy initiation. Although COVID-19 infection, like most other viruses, can potentially worsen patients with pre-existing autoimmunity, there is no evidence that patients with autoimmune neurological diseases stable on common immunotherapies are facing increased risks of infection.\n\nGuillain-Barré syndromes (GBSs) comprise a spectrum of polyneuropathies characterized by acute (within 1–4 weeks) ascending motor weakness, mild or moderate sensory abnormalities, occas"}

{"project":"LitCovid-sentences","denotations":[{"id":"T17","span":{"begin":137,"end":148},"obj":"Sentence"},{"id":"T18","span":{"begin":149,"end":321},"obj":"Sentence"},{"id":"T19","span":{"begin":322,"end":586},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"dressed; the role of complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed.\n\nConclusions\nEmerging data indicate that COVID-19 can trigger not only GBS but other autoimmune neurological diseases necessitating vigilance for early diagnosis and therapy initiation. Although COVID-19 infection, like most other viruses, can potentially worsen patients with pre-existing autoimmunity, there is no evidence that patients with autoimmune neurological diseases stable on common immunotherapies are facing increased risks of infection.\n\nGuillain-Barré syndromes (GBSs) comprise a spectrum of polyneuropathies characterized by acute (within 1–4 weeks) ascending motor weakness, mild or moderate sensory abnormalities, occas"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T18","span":{"begin":426,"end":438},"obj":"Phenotype"},{"id":"T19","span":{"begin":643,"end":659},"obj":"Phenotype"}],"attributes":[{"id":"A18","pred":"hp_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/HP_0002960"},{"id":"A19","pred":"hp_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/HP_0001271"}],"text":"dressed; the role of complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed.\n\nConclusions\nEmerging data indicate that COVID-19 can trigger not only GBS but other autoimmune neurological diseases necessitating vigilance for early diagnosis and therapy initiation. Although COVID-19 infection, like most other viruses, can potentially worsen patients with pre-existing autoimmunity, there is no evidence that patients with autoimmune neurological diseases stable on common immunotherapies are facing increased risks of infection.\n\nGuillain-Barré syndromes (GBSs) comprise a spectrum of polyneuropathies characterized by acute (within 1–4 weeks) ascending motor weakness, mild or moderate sensory abnormalities, occas"}